Professor | Chuanhui Han | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Chuanhui Han

Contact Information

chuanhui.han@bjmu.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2005-2009 Bachelor: Beijing Institute of Technology 2009-2015 PhD: Institute of Biophysics, Chinese Academy of Sciences Published over 20 papers in renowned journals
Work Experience	2021.12-Present Assistant Professor (Tenure-track), Peking University International Cancer Institute 2016-2021 Postdoctoral Researcher, University of Texas Southwestern Medical Center

University/Lab Affiliation and Title

Peking University

Faculty

Basic Medical Sciences

Academic Background & Achievements

Work Experience

2021.12-Present Assistant Professor (Tenure-track), Peking University International Cancer Institute
2016-2021 Postdoctoral Researcher, University of Texas Southwestern Medical Center

Areas of Focus	Tumor immunology Tumor immune tolerance mechanisms Development of novel cancer immunotherapies
Publications	The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation, Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, Hasan Z#, Fu Y#, 2021 Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling, Han C, Liu Z, Zhang Y, Shen A, Dong C, Zhang A, Moor C, Cao X, Ren Z, Lu C, Qiao J#, Fu Y#, 2020 β-catenin regulates tumor-derived PD-L1, Han C, Fu Y, 2020 Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy, Han C. Zhang A, Liu Z, C Moore. Fu Y#, 2020 Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity, Liu Z, Han C, Dong C, Shen A, Hsu E, Ren Z, Lu C, Liu L, Zhang A, Timmerman C, Pu Y, Wang Y, Chen M, Qiao J, Fu Y#, 2019

Areas of Focus

Tumor immunology
Tumor immune tolerance mechanisms
Development of novel cancer immunotherapies

Publications

The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation, Han C*, Godfrey V*, Liu Z, Han Y, Liu L, Peng H, Hasan Z#, Fu Y#, 2021
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling, Han C*, Liu Z*, Zhang Y, Shen A, Dong C, Zhang A, Moor C, Cao X, Ren Z, Lu C, Qiao J#, Fu Y#, 2020
β-catenin regulates tumor-derived PD-L1, Han C, Fu Y, 2020
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy, Han C. Zhang A, Liu Z, C Moore. Fu Y#, 2020
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity, Liu Z*, Han C*, Dong C, Shen A, Hsu E, Ren Z, Lu C, Liu L, Zhang A, Timmerman C, Pu Y, Wang Y, Chen M, Qiao J, Fu Y#, 2019

Tumor Immunology Immune Tolerance Mechanisms Novel Cancer Therapies Development Research

Xian Wang - Peking University

Xiaowei Zhang - Peking University

Ying Zhao - Peking University

View All

Personal Information